BioNTech announced that the Company and the Weizmann Institute of Science signed a Memorandum of Understanding, MoU. As part of this MoU, scientists from a variety of disciplines from BioNTech and the Weizmann Institute will collaborate in basic and applied research with the aim to better understand various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The joint research will be conducted at BioNTech’s newly established mRNA Excellence Center and in Weizmann Institute laboratories. The MoU supports BioNTech’s long-term strategy to discover, research and develop innovative vaccines and therapies for diseases with high unmet medical need. The Company’s mRNA Excellence Center will be based within the Weizmann Science Park in Ness Ziona. BioNTech expects the center to start operations by the end of 2023. "We are pleased to establish mRNA research laboratories on the campus of the Weizmann Institute of Science," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "Our initiative aims to foster collaborations with top researchers to advance multidisciplinary research and accelerate the development of innovative solutions to tackle some of the world’s most pressing health challenges."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
- BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
- Pharma Industry Could Benefit from Rise in Medicine Spending
- FDA sees preliminary safety signal for older users of Pfizer bivalent vaccine
- BNTX Jumps after Announcing InstaDeep Acquisition
